Vosoritide

Drug

Also known as: Voxzogo, VOXZOGO®

Related News

BioMarin raises 2026 revenue guidance after Amicus acquisition and FDA PALYNZIQ expansion

May 05, 2026

BioMarin reported first-quarter 2026 revenue of $766 million and raised full-year guidance to $3.825 billion-$3.925 billion. The company highlighted FDA approval of PALYNZIQ for adolescents and upcoming Phase 3 readouts for BMN 401 and VOXZOGO.

BridgeBio's Infigratinib Succeeds in Phase 3 Achondroplasia Trial, Plans 2026 Regulatory Filing

Feb 13, 2026

BridgeBio Pharma reported positive Phase 3 results for oral infigratinib in children with achondroplasia, meeting primary and secondary endpoints with superior growth velocity and the first statistically significant improvement in body proportionality. The company plans regulatory submissions in the second half of 2026.